Mereo BioPharma Group plc
For the period ended Dec 31, 2025. Filed Mar 19, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 19, 2026
MREO$0.30+4.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated statements of changes in equity
| Ordinary shares · Treasury shares · Additional · Accumulatedother · Total | ||||||||
|---|---|---|---|---|---|---|---|---|
| Shares | Par value | Shares | Par value | paid-in capital | comprehensiveloss | Accumulated deficit | shareholders’ equity | |
| Balance, December 31, 2023 | 701,217,089 | $2,775 | 923,400 | $(1,230) | $486,107 | $(17,485) | $(419,630) | $50,537 |
| Net loss | — | — | — | — | — | — | (43,253) | (43,253) |
| Foreign currency translation adjustments | — | — | — | — | — | (1,364) | — | (1,364) |
| Share-based compensation | — | — | — | — | 7,390 | — | — | 7,390 |
| Exercise of share options | 2,685,420 | 11 | (210,485) | 280 | (299) | — | — | (8) |
| Delivery of shares on vesting of restricted stock units | 433,880 | 2 | (712,915) | 950 | (953) | — | — | (1) |
| Delivery of shares on vesting of performance based restricted stock units | 6,690,755 | 25 | — | — | (67) | — | — | (42) |
| Issuance of shares, net of discount | 64,700,890 | 246 | — | — | 48,503 | — | — | 48,749 |
| Transaction costs on issuance of shares | — | — | — | — | (1,039) | — | — | (1,039) |
| Balance, December 31, 2024 | 775,728,034 | $3,059 | — | $— | $539,642 | $(18,849) | $(462,883) | $60,969 |
| Net loss | — | — | — | — | — | — | (41,878) | (41,878) |
| Foreign currency translation adjustments | — | — | — | — | — | 8,026 | — | 8,026 |
| Share-based compensation | — | — | — | — | 7,598 | — | — | 7,598 |
| Exercise of share options | 174,100 | 1 | — | — | 38 | — | — | 39 |
| Delivery of shares on vesting of restricted stock units | 1,201,310 | 5 | — | — | (5) | — | — | — |
| Transaction costs on issuance of shares | — | — | — | — | (65) | — | — | (65) |
| Conversion of convertible loan notes | 17,105,450 | 64 | — | — | 5,676 | — | — | 5,740 |
| Exercise of warrants | 1,449,610 | 6 | — | — | 481 | — | — | 487 |
| Transfer between reserves | — | — | — | — | (3,743) | — | 3,743 | — |
| Balance, December 31, 2025 | 795,658,504 | $3,135 | — | $— | $549,622 | $(10,823) | $(501,018) | $40,916 |
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.